Algaktiv launched Exometics G, a biomimetic exosome technology engineered from microalgae. Exometics G delivers superior skin renewal, elasticity, and anti-aging benefits while overcoming the ethical, regulatory, and consumer concerns of first-generation exosomes.

Unlike currently available exosome solutions, which often provide unquantified and
inconsistent vesicle concentrations, Exometics G is precisely dosed, with over 10 billion
vesicles/mL — allowing brands to claim above 10 millions of exosomes per drop in a
formulated cream or serum, ensuring superior biological activity and efficacy in final
formulations.

With patented bioengineering process, a controlled 150nm particle size for optimal cell
delivery, and unrivaled consistency, Exometics G is setting a new gold standard for
next-generation skincare, according to the company.

More info: Algativ, www.algativ.com